Literature DB >> 14514736

Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.

Danxia Zheng1, Marieka Wolfe, Benjamin D Cowley, Darren P Wallace, Tamio Yamaguchi, Jared J Grantham.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) progresses to renal insufficiency in >50% of patients and is characterized by interstitial inflammation and fibrosis in the end stage. In a rat model of ADPKD, monocytes accumulate within the renal interstitium in association with increased levels of monocyte chemoattractant protein-1 (MCP-1) in cyst mural cells and increased excretion of this chemokine into the urine. For determining the extent to which this chemokine is abnormally expressed in patients with ADPKD, a cross-section study was performed of MCP-1 in urine, serum, and cyst fluid and MCP-1 production by mural epithelial cells cultured from the cysts of human patients with ADPKD. Upper boundaries for urinary MCP-1 excretion (>263 pg/mg creatinine) and serum creatinine concentration (>1.5 mg/dl) determined in 19 normal individuals were used to sort 55 ADPKD patients into three groups. In group 1 (n = 13), urine MCP-1 excretion (136 +/- 14 pg/mg creatinine) was not different from normal volunteers (152 +/- 16 pg/mg); serum creatinine levels and urine total protein excretion were normal as well. In group 2 (n = 27), urine MCP-1 excretion was increased (525 +/- 39 pg/mg creatinine), but serum creatinine levels and urine protein excretion were not different from normal. In group 3 (n = 15), urine MCP-1 excretion increased further (1221 +/- 171 pg/mg), serum creatinine levels increased to 4.3 +/- 0.8 mg/dl, and urine protein excretion rose to 0.64 +/- 0.28 mg/mg creatinine. Serum MCP-1 levels of ADPKD patients (84 +/- 9.9 pg/ml; n = 15) did not differ from normal. Levels of MCP-1 much higher than in serum or urine were found in cyst fluids obtained from nephrectomy specimens (range, 767 to 40,860 pg/ml; mean, 6434 +/- 841 pg/ml; n = 73). Polarized, confluent cultures of ADPKD cyst epithelial cells secreted MCP-1 into the apical fluid to levels eightfold greater than in the basolateral medium. Similar results were obtained with tubule epithelial cells cultured from normal human renal cortex. On the basis of these results, it is concluded that urinary excretion of MCP-1 is increased in the majority of adult patients with ADPKD and that the source of some of this chemokine may be the mural epithelium of cysts. Furthermore, it seemed that urinary MCP-1 excretion may have increased in these ADPKD patients before appreciable increases in serum creatinine concentration or urine protein excretion were detected. It is reasonable to include urine MCP-1 excretion among candidate surrogate markers in controlled, longitudinal studies of ADPKD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514736     DOI: 10.1097/01.asn.0000088720.61783.19

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  55 in total

1.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

2.  Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Authors:  Lucy X Fan; Xia Zhou; William E Sweeney; Darren P Wallace; Ellis D Avner; Jared J Grantham; Xiaogang Li
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

Review 3.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

4.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

Review 5.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

6.  Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity.

Authors:  Kumiko Nishihara; Satohiro Masuda; Haruka Shinke; Aiko Ozawa; Takaharu Ichimura; Atsushi Yonezawa; Shunsaku Nakagawa; Ken-Ichi Inui; Joseph V Bonventre; Kazuo Matsubara
Journal:  Biochem Pharmacol       Date:  2013-01-02       Impact factor: 5.858

7.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; James E Bost; Vicente E Torres; Lisa Guay-Woodford; Kyongtae Ty Bae; Douglas Landsittel; Jie Li; Bernard F King; Diego Martin; Louis H Wetzel; Mark E Lockhart; Peter C Harris; Marva Moxey-Mims; Mike Flessner; William M Bennett; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

Review 8.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 9.  Autosomal dominant polycystic kidney disease and transplantation.

Authors:  Mariusz Niemczyk; Stanisław Niemczyk; Leszek Paczek
Journal:  Ann Transplant       Date:  2009 Oct-Dec       Impact factor: 1.530

10.  Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion.

Authors:  Ana P Bastos; Klaus Piontek; Ana M Silva; Dino Martini; Luis F Menezes; Jonathan M Fonseca; Ivone I Fonseca; Gregory G Germino; Luiz F Onuchic
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.